Pheochromocytoma: Advances in Genetics, Diagnosis, Localization, and Treatment

Hematology/Oncology Clinics of North America

Volumn 21, Issue 3, 2007, Pages 509-525

  Mittendorf, Elizabeth A ^a   Evans, Douglas B ^a   Lee, Jeffrey E ^a   Perrier, Nancy D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CYCLOPHOSPHAMIDE; DACARBAZINE; IODINE 131; METIROSINE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PRAZOSIN; PROTEIN RET; SUCCINATE DEHYDROGENASE; TERAZOSIN; VINCRISTINE; VON HIPPEL LINDAU PROTEIN;

ADRENAL MEDULLA; CANCER INCIDENCE; CLINICAL FEATURE; DRUG MECHANISM; GENE MUTATION; HUMAN; HYPERTENSION; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SIPPLE SYNDROME; STURGE WEBER SYNDROME; TUBEROUS SCLEROSIS; TUMOR LOCALIZATION; UNITED STATES; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; CATECHOLAMINES; DISEASE PROGRESSION; HUMANS; MUTATION; PHEOCHROMOCYTOMA;

EID: 34249688631     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.04.012     Document Type: Review

References (88)

1. Pederson L.C., and Lee J.E. Pheochromocytoma. Curr Treat Options Oncol 4 (2003) 329-337
2. Bryant J., Farmer J., Kessler L.J., et al. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95 (2003) 1196-1204
3. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
4. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
5. Woodward E.R., Eng C., McMahon R., et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 6 (1997) 1051-1056
6. Yip L., Cote G.J., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138 (2003) 409-416
7. Linehan WM, Walther MM. Molecular genetic abnormalities associated with pheochromocytoma. In: Pacak K, moderator. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:316-7.
8. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276 (1996) 1575-1579
9. Gagel R.F., Tashjian A.H., Cummings T., et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a: an 18-year experience. N Engl J Med 318 (1988) 478-484
10. Kaltsas G.A., Papadogias D., and Grossman A.B. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 31 (2004) 61-75
11. Lips K.J.M., Van Der Sluys Veer J., Alleman A., et al. Bilateral occurrence of pheochromocytoma in patients with multiple endocrine neoplasia syndrome type 2A (Sipple's syndrome). Am J Med 70 (1981) 1051-1060
12. Lairmore T.C., Ball D.W., Baylin S.B., et al. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 217 (1993) 595-603
13. Yip L., Lee J.E., Shapiro S.E., et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198 (2004) 525-535
14. Latif F., Duh F.M., Gnarra J., et al. von Hippel-Lindau syndrome: cloning and identification of the plasma membrane Ca(++)-transporting ATPase isoform 2 gene that resides in the von Hippel-Lindau gene region. Cancer Res 53 (1993) 861-867
15. Glenn G.M., Choyke P.L., Zbar B., et al. von Hippel-Lindau disease: clinical review and molecular genetics. In: Anderson E.E. (Ed). Problems in urologic surgery: benign and malignant tumors of the kidney (1990), Lippincott, Philadelphia 312-330
16. Walther MM. Management of pheochromocytoma. In: Pacak K, moderator. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:323-3.
17. Chen F., Kishida T., Yao M., et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5 (1995) 66-75
18. Walther M.M., Reiter R., Keiser H.R., et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162 (1999) 659-664
19. Delman KA, Shapiro SE, Jonasch EW, et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg 2006;30:665-9.
20. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287 (2000) 848-851
21. Astuti D., Douglas F., Lennard T.W.J., et al. Germline SDHD mutation in familial pheochromocytoma. Lancet 357 (2001) 1181-1182
22. Gimm O., Armanios M., Dziema H., et al. Somatic and occult germline mutations in SDHD, a mitochondrial complex II gene, in non-familial pheochromocytomas. Cancer Res 60 (2000) 6822-6825
23. Neumann H.P.H., Bausch B., McWhinney S.R., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346 (2002) 1459-1466
24. Gimenez-Roqueplo A.P., Favier J., Restin P., et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63 (2003) 5615-5621
25. Grant C.S. Pheochromocytoma. In: Clark O.H., and Duh Q.Y. (Eds). Textbook of endocrine surgery (1997), WB Saunders, Philadelphia 513-522
26. Pacak K. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134 (2001) 315-329
27. Duh Q.-Y. Adrenal incidentalomas. Br J Surg 89 (2002) 1347-1349
28. Manger W.M., and Gifford Jr. R.W. Clinical and experimental pheochromocytoma (1996), Blackwell Science, Cambridge (MA)
29. Mantero F., Terzolo M., Amaldi G., et al. A survey on adrenal incidentaloma in Italy: study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85 (2000) 637-644
30. Sutton M.G., Sheps S.G., and Lie J.T. Prevalence of clinically unsuspected pheochromocytoma: review of a 50-year autopsy series. Mayo Clin Proc 56 (1981) 354-360
31. Eisenhofer G. Biochemical diagnosis of pheochromocytoma. In: Pacak K, moderator. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:317-320.
32. Eisenhofer G., Lenders J.W., Linehan W.M., et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340 (1999) 1872-1879
33. Lenders J.W.M., Pacak K., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA 287 (2002) 1427-1434
34. Raber W., Raffesberg W., Bischof M., et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160 (2000) 2957-2963
35. Eisenhofer G., Friberg P., Pacak K., et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism?. Clin Sci 88 (1995) 533-542
36. Eisenhofer G., Keiser H., Friberg P., et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methytransferase within tumors. J Clin Endocrinol Metab 83 (1998) 2175-2185
37. Sawka A.M., Jaeschke R., Singh R.J., et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88 (2003) 553-558
38. Francis I.R., and Korobkin M. Pheochromocytoma. Radiol Clin North Am 34 (1996) 1101-1112
39. Goldstein R.E., O'Neil Jr. J.A., Holcomb G.W., et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 229 (1999) 755-766
40. Ilias I., and Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89 (2004) 479-491
41. Mannelli M., Ianni L., Cilotti A., et al. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141 (1999) 619-624
42. Maurea S., Cuocolo A., Reynolds J.C., et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 34 (1993) 173-179
43. Maurea S., Cuocolo A., Reynolds J.C., et al. Diagnostic imaging in patients with paragangliomas: computed tomography magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med 40 (1996) 365-371
44. Quint L.E., Glazer G.M., Francis I.R., et al. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 165 (1987) 89-93
45. Honigschnabl S., Gallo S., Niederle B., et al. How accurate is MR imaging in characterization of adrenal masses: update of a long-term study. Eur J Radiol 41 (2002) 113-122
46. Mayo-Smith W.W., Boland G.W., Noto R.B., et al. State-of-the-art adrenal imaging. Radiographics 21 (2001) 995-1012
47. Bravo E.L. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 14 (1994) 356-368
48. Sisson J.C., and Shulkin B.L. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 43 (1999) 217-223
49. Fujita A., Hyodoh H., Kawamura Y., et al. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 25 (2000) 440-442
50. Pacak K., Ilias I., Adams K.T., et al. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 257 (2005) 60-68
51. Gelfand M.J., Elgazzar A.H., Kriss V.M., et al. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 35 (1994) 1753-1757
52. Shulkin B.L., Thompson N.W., Shapiro B., et al. Pheochromocytomas: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology 212 (1999) 35-41
53. Trampal C., Engler H., Juhlin C., et al. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 230 (2004) 423-428
54. Shulkin B.L., Wieland D.M., Schwaiger M., et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 33 (1992) 1125-1131
55. Roman S.A. Pheochromocytoma. In: Cameron J.L. (Ed). Current surgical therapy. 8th edition (2003), Elsevier Mosby, Philadelphia 569-574
56. Pullerits J., Eis S., and Balfe J.W. Anaesthesia for phaeochromocytoma. Can J Anaesth 35 (1988) 526-534
57. Levine S.N., and McDonald J.C. The evaluation and management of pheochromocytomas. Adv Surg 17 (1984) 281-313
58. Vargas H.I., Kavoussi L.R., Bartlett D.L., et al. Laparoscopic adrenalectomy: a new standard of care. Urology 49 (1997) 673-678
59. Aldrighetti L., Giacomelli M., Calori G., et al. Impact of minimally invasive surgery on adrenalectomy for incidental tumors: comparison with laparotomic technique. Int Surg 82 (1997) 160-164
60. Brunt L.M., Doherty G.M., Norton J.A., et al. Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms. J Am Coll Surg 183 (1996) 1-10
61. Gagner M., Pomp A., Heniford B.T., et al. Laparoscopic adrenalectomy: lessons learned from 100 consecutive patients. Ann Surg 226 (1997) 238-247
62. Guazzoni G., Montorsi F., Bocciardi A., et al. Transperitoneal laparoscopic versus open adrenalectomy for benign hyperfunctioning adrenal tumors: a comparative study. J Urol 153 (1995) 1597-1600
63. Thompson G.B., Grant C.S., van Heerden J.A., et al. Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. Surgery 122 (1997) 1132-1136
64. Walz M, Alesina PF, Wenger FA, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 160 tumors in 126 patients. World J Surg 2006;30:899-908.
65. Jansson S., Tisell L.E., Fjalling M., et al. Early diagnosis of and surgical strategy for adrenal medullary disease in MEN 2 gene carriers. Surgery 103 (1988) 11-18
66. van Heerden J.A., Sizemore G.W., Carney J.A., et al. Surgical management of the adrenal glands in multiple endocrine neoplasia type II syndrome. World J Surg 8 (1984) 612-621
67. de Graaf J.S., Dullaart R.P.F., and Zwierstra R.P. Complications after bilateral adrenalectomy for phaeochromocytoma in multiple endocrine neoplasia type 2-a plea to conserve adrenal function. Eur J Surg 165 (1999) 843-846
68. Richard S., Beigelman C., Duclos J.M., et al. Pheochromocytoma as the first manifestation of von Hippel-Lindau disease. Surgery 116 (1994) 1076-1081
69. Casanova S., Rosenberg-Bourgin M., Farkas D., et al. Phaeochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases. Clin Endocrinol (Oxf) 38 (1993) 531-537
70. Lee J.E., Curley S.A., Gagel R.F., et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120 (1996) 1064-1071
71. Evans D.B., Lee J.E., Merrell R.C., et al. Adrenal medullary disease in multiple endocrine neoplasia type 2: appropriate management. Endocrinol Metab Clin North Am 23 (1994) 167-176
72. Neumann H.P.H., Reincke M., Bender B.U., et al. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 84 (1999) 2608-2610
73. Baghai M., Thompson G.B., Young Jr. W.F., et al. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 137 (2002) 682-689
74. Walz M.K., Peitgen K., Diesing D., et al. Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasia. World J Surg 28 (2004) 1323-1329
75. Proye C.A., Vix M., Jansson S., et al. The pheochromocytoma: a benign intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?. World J Surg 18 (1994) 467-472
76. van Heerden J.A., Roland C.F., Carney J.A., et al. Long-term evaluation following resection of apparently benign pheochromocytomas(s)/paragangliomas(s). World J Surg 14 (1990) 325-329
77. Proye C., Vix M., Goropoulos A., et al. High incidence of malignant pheochromocytoma in a surgical unit: 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest 15 (1992) 651-663
78. Plouin P.F., Chatellier G., Fofol I., et al. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29 (1997) 1133-1139
79. Kopf D., Goretzki P.E., and Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 127 (2001) 143-155
80. Mundeschenk J., and Lehnert H. Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 106 (1998) 373-376
81. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20 (1997) 648-658
82. Troncone L., and Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 43 (1999) 344-355
83. Averbuch S.D., Steakley C.S., Young R.C., et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109 (1988) 267-273
84. Tada H., Tyler D.S., and Lee J.E. Adrenal tumors. In: Feig B.W., Berger D.H., and Fuhrman G.M. (Eds). The M. D. Anderson surgical oncology handbook. 3rd edition (2003), Lippincott Williams & Wilkins, Philadelphia 352-369
85. Kopf D., Bockisch A., Steinert H., et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 46 (1997) 39-44
86. Meco D., Lasorella A., Riccardi A., et al. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 35 (1999) 1227-1234
87. Sisson J.C., Shapiro B., Shulkin B.L., et al. Treatment of malignant pheochromocytomas with 131I-metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 22 (1999) 364-370
88. Zielke A., Middeke M., Hoffman S., et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated with malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132 (2002) 1056-1063